WEDNESDAY, Sept. 28 (HealthDay News) -- DNA repair capacity (DRC) in peripheral lymphocytes is a significant, independent predictor of survival for patients with non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy, according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Li-E Wang, M.D., from The University of Texas M.D. Anderson Cancer Center in Houston, and colleagues investigated whether DRC in peripheral lymphocytes predicted survival in 591 patients with NSCLC who received first-line platinum-based chemotherapy. Blood samples collected prior to chemotherapy initiation were used to determine DRC in cultured T lymphocytes using the host-cell reactivation assay.
The investigators found that DRC in peripheral lymphocytes was inversely associated with patient survival. Patients in the highest tertile of DRC exhibited significantly worse overall and three-year survival compared to those in the lowest DRC tertile (adjusted hazard ratio, 1.33 and 1.35, respectively). This trend was more prominent in patients with adenocarcinoma, early-stage tumors, or squamous cell carcinoma.
"It is promising to use DRC in peripheral lymphocytes as a prognostic factor to guide tailored individual therapeutics for patients with NSCLC," the authors write.
Two of the study authors disclosed financial relationships with AstraZeneca.
Abstract
Full Text (subscription or payment may be required)
